Suppr超能文献

全主动脉弓替换加冷冻象鼻术后治疗远端胸腹主动脉病变的开窗分支血管腔内修复

Fenestrated-branched endovascular repair for distal thoracoabdominal aortic pathology after total aortic arch replacement with frozen elephant trunk.

机构信息

University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.

Division of Vascular Surgery, Mayo Clinic, Rochester, MN; University of Texas Health Sciences Centre at Houston, McGovern Medical School, Houston, TX.

出版信息

J Vasc Surg. 2022 Oct;76(4):867-874. doi: 10.1016/j.jvs.2022.04.035. Epub 2022 Jun 10.

Abstract

OBJECTIVE

To report the outcomes of fenestrated-branched endovascular repair (FBEVAR) for thoracoabdominal aortic pathology after total aortic arch replacement with frozen elephant trunk (TAR+FET).

METHODS

Interrogation of prospectively maintained databases from four high-volume aortic centers identified consecutive patients treated with distal FBEVAR after prior TAR+FET between August 2013 and September 2020. The primary end point was 30-day/in-hospital mortality. Secondary end points were technical success, early clinical success, midterm survival, and freedom from reintervention. Data are presented as median (interquartile range).

RESULTS

A total of 39 patients (21 men; median age, 73 years [67-75 years]) with degenerative (n = 22) and postdissection thoracoabdominal aortic aneurysms (n = 17) (median diameter, 71 mm [61-78 mm]) were identified. Distal FBEVAR was intended in 27 patients (median interval, 9.8 months [6.2-16.6 months]), anticipated in 7, and unexpected in 5. A total of 31 patients had a two- (n = 24) or three-stage (n = 7) distal FBEVAR. Renovisceral target vessel preservation was 99.3% (145 of 146). Early primary and secondary technical success was 92% and 97%, respectively. Thirty-day mortality was 2.6% (n = 1; respiratory failure and spinal cord ischemia [SCI]). Six survivors also developed SCI, which was associated with complete (n = 4) or partial recovery (n = 2) at hospital discharge. No patients required renal replacement therapy or suffered a stroke. Early clinical success was 95%. Median follow-up was 30.5 months (23.7-49.7 months). Eleven patients required 16 late reinterventions. Estimated 3-year survival and freedom from reintervention were 84% ± 6% and 63% ± 10%, respectively.

CONCLUSIONS

Distal FBEVAR after prior TAR+FET is associated with high technical success and low early mortality. The risk of SCI is significant although the majority of patients demonstrate full or partial recovery before hospital discharge. Midterm patient survival is favorable, but there remains a high requirement for late reintervention. FBEVAR represents an acceptable alternative to distal open thoracoabdominal aortic aneurysm repair.

摘要

目的

报告在全主动脉弓置换联合冷冻象鼻(TAR+FET)后,对胸主动脉腹主动脉病变行开窗分支血管腔内修复术(FBEVAR)的结果。

方法

从四个大容量主动脉中心前瞻性维护的数据库中查询,确定了 2013 年 8 月至 2020 年 9 月期间,在 TAR+FET 后接受远端 FBEVAR 治疗的连续患者。主要终点是 30 天/住院死亡率。次要终点是技术成功、早期临床成功、中期生存率和免于再干预。数据以中位数(四分位距)表示。

结果

共确定了 39 名患者(21 名男性;中位年龄 73 岁[67-75 岁]),包括退行性病变(n=22)和主动脉夹层后胸主动脉腹主动脉瘤(n=17)(中位直径 71mm[61-78mm])。27 名患者(中位间隔时间为 9.8 个月[6.2-16.6 个月])计划进行远端 FBEVAR,7 名患者预计进行远端 FBEVAR,5 名患者意外进行远端 FBEVAR。共有 31 名患者进行了两阶段(n=24)或三阶段(n=7)远端 FBEVAR。肾内脏靶血管的保留率为 99.3%(145/146)。早期主要和次要技术成功率分别为 92%和 97%。30 天死亡率为 2.6%(n=1;呼吸衰竭和脊髓缺血[SCI])。6 名幸存者还发生了 SCI,出院时完全(n=4)或部分恢复(n=2)。没有患者需要肾脏替代治疗或发生中风。早期临床成功率为 95%。中位随访时间为 30.5 个月(23.7-49.7 个月)。11 名患者需要进行 16 次晚期再介入。估计 3 年生存率和免于再干预率分别为 84%±6%和 63%±10%。

结论

在 TAR+FET 后进行远端 FBEVAR 与高技术成功率和低早期死亡率相关。尽管大多数患者在出院前完全或部分恢复,但 SCI 的风险仍然很大。中期患者生存率良好,但仍需要晚期再干预。FBEVAR 是一种可接受的替代方案,用于治疗远端开放性胸主动脉腹主动脉瘤。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验